OTLK — Outlook Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1649989 ·
Last close
$0.56
Market Cap
$137.30M
52W High
$2.54
52W Low
$0.16
ADV30
4,794,090
Next earnings
2026-08-14
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 8,700 | -8,265 | -10,810,209 | -20,319,272 | 26,184,850 | 11,242,068 | 36,577,417 |
| Mar 2026 | 127,439 | -21,888 | -14,026,987 | -4,453,081 | 21,892,406 | 7,748,226 | 50,887,177 |
| Dec 2025 | -1,207,833 | -1,237,459 | -13,483,952 | -23,058,135 | 18,238,574 | 8,677,424 | 56,788,039 |
| Sep 2025 | -91,787 | -1,008,302 | -17,314,606 | -13,292,769 | 18,584,183 | 8,083,085 | 50,771,844 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-47,045,522
Investing CF
—
Financing CF
$47,237,435
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.48
As of
2026-08-23
Balance + Analyst (yfinance extras)
Retained Earnings
$-633,220,979
Inventory
$3,344,242
Receivables
$2,719,828
ST Investments
—
EBIT TTM
$-62,197,332
Pretax Income TTM
$-62,511,116
Interest Exp TTM
$313,507
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$-1,163,481
EBITDA
$-55,531,736
Free Cash Flow
$-37,357,632
Enterprise Value
$167,864,464
Total Cash
$11,242,068
Total Debt
$18,431,144
Shares Out
243,447,554
Trailing EPS
$-0.70
Book Value
$-0.06
ROE
—
ROA
-143.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Sep 2025 | 1,413,535 | -67,061,666 | -62,424,863 | 18,584,183 | 50,771,844 | -32,187,661 | -51,829,437 |
| Sep 2024 | 0 | -71,703,235 | -75,366,714 | 28,823,154 | 101,899,664 | -73,076,510 | -68,793,858 |
| Sep 2023 | 0 | -53,126,382 | -58,982,668 | 32,300,601 | 46,738,378 | -14,437,777 | -42,973,398 |
| Sep 2022 | 0 | -63,070,753 | -66,052,264 | 28,527,751 | 19,791,180 | 8,736,571 | -56,674,559 |
TTM Snapshot
Revenues TTM
$-3,437,784
NetIncome TTM
$-60,956,487
OpCashFlow TTM
—
Assets (Latest)
$21,892,406
Forward EPS
$-0.12
Max Pain — expiry 2027-01-15
max pain strike: $0.50 · spot: $0.57 · call oi: 16,629 · put oi: 2,734
Expected Move to 2027-01-15:
±$0.33
(57.00%) —
implied range
$0.25 –
$0.90
· ATM straddle on $0.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AVXL | ANAVEX LIFE SCIENCES CORP. | $142.75M | $1.54 | — |
| ARMP | Armata Pharmaceuticals, Inc. | $143.52M | $3.86 | — |
| MOLN | MOLECULAR PARTNERS AG | $145.94M | $3.81 | — |
| VYGR | Voyager Therapeutics, Inc. | $146.03M | $2.37 | — |
| HUMA | Humacyte, Inc. | $124.20M | $0.45 | — |
News headlines (Yahoo Finance, 1h cache)
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
2026-10-09 12:30 · Yahoo
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
2026-09-11 11:00 · Yahoo
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
2026-08-27 20:05 · Yahoo
Outlook Therapeutics (OTLK) Stock May Be No Bargain With Approval But Weak Balance Sheet
2026-08-15 06:12 · Yahoo
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
2026-08-14 11:15 · Yahoo
Why Did OTLK Stock Crash In Pre-Market Today?
2026-08-13 10:31 · Yahoo
Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
2026-08-12 20:01 · Yahoo
OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp
2026-08-17 14:00 · Yahoo
Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion
2026-10-06 13:20 · Yahoo
Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
2026-10-01 13:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.